Andrew J. Wagner, MD, PhD

Assistant Professor, Department of Medicine, Harvard Medical School

Active Medical Staff, Adult Oncology, Dana-Farber Cancer Institute

Contact Info

Andrew Wagner
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Phone: 617-632-5204
Fax: 617-632-3408
awagner@partners.org

Assistant

Courtney Haskett
Administrative Assistant
Center for Sarcoma & Bone Oncology
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: D-1212
Phone: 617-632-6563
Fax: 617-632-3408
courtney_haskett@dfci.harvard.edu

DF/HCC Program Affiliation

Sarcoma
Translational Pharmacology and Early Therapeutic Trials

Research Abstract

Soft tissue sarcomas and bone tumors represent a heterogeneous group of cancers derived from mesenchymal cells. In general, these tumors are often refractory to standard available chemotherapeutic agents. We are interested in identifying critical pathways necessary for these tumors to form and survive, and in developing novel therapeutics that we will test both pre-clinically and in early clinical trials.

Publications

View All Publications

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Andrew J. Wagner, MD, PhD Assistant Professor, Department of Medicine, Harvard Medical School Active Medical Staff, Adult Oncology, Dana-Farber Cancer Institute Contact Info Andrew Wagner Dana-Farber Cancer Institute 450 Brookline Avenue Boston, MA, 02215 Phone: 617-632-5204 Fax: 617-632-3408 awagner@partners.org Assistant Courtney Haskett Administrative Assistant Center for Sarcoma & Bone Oncology Dana-Farber Cancer Institute 450 Brookline Avenue Boston, MA, 02215 Mailstop: D-1212 Phone: 617-632-6563 Fax: 617-632-3408 courtney_haskett@dfci.harvard.edu DF/HCC Program Affiliation Sarcoma Translational Pharmacology and Early Therapeutic Trials Research Abstract Soft tissue sarcomas and bone tumors represent a heterogeneous group of cancers derived from mesenchymal cells. In general, these tumors are often refractory to standard available chemotherapeutic agents. We are interested in identifying critical pathways necessary for these tumors to form and survive, and in developing novel therapeutics that we will test both pre-clinically and in early clinical trials. Publications View All Publications
Site Map Site Feedback Web Privacy Policy